HUTCHMED (NASDAQ:HCM) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of HUTCHMED (NASDAQ:HCM) from a hold rating to a buy rating in a research report sent to investors on Wednesday.

Separately, Cantor Fitzgerald restated an overweight rating on shares of HUTCHMED in a research note on Friday, January 12th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, HUTCHMED presently has an average rating of Moderate Buy and an average target price of $29.70.

HUTCHMED Stock Down 0.3 %

HUTCHMED stock opened at $16.80 on Wednesday. The firm has a 50 day moving average of $14.93 and a 200 day moving average of $16.62. HUTCHMED has a 12-month low of $10.68 and a 12-month high of $20.73. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.72 and a quick ratio of 2.60.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Acadian Asset Management LLC bought a new stake in shares of HUTCHMED during the third quarter worth $3,268,000. UniSuper Management Pty Ltd bought a new stake in shares of HUTCHMED in the second quarter valued at about $6,838,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of HUTCHMED in the third quarter valued at about $444,000. Hsbc Holdings PLC bought a new stake in shares of HUTCHMED in the third quarter valued at about $380,000. Finally, Vanguard Personalized Indexing Management LLC bought a new stake in shares of HUTCHMED in the third quarter valued at about $196,000. 8.82% of the stock is owned by hedge funds and other institutional investors.

HUTCHMED Company Profile

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.